In AML, mutant IDH1/2 enzymes convert α-ketoglutarate into the oncometabolite 2-hydroxyglutarate (2-HG), which accumulates in tumor tissues and patient serum, thereby suppressing immune function. Here, IDH1 is linked to acute myeloid leukemia.